Abstracts tagged "classification criteria"

Abstract Number: L07 • ACR Convergence 2024
The Classification Criteria for Anti-Synthetase Syndrome (Class) Project
Giovanni Zanframundo¹, Sara Faghihi Kashani², Akira Yoshida³, Eduardo Dourado⁴, Iazsmin Bauer Ventura⁵, Daphne Rivero Gallegos⁶, Aravinthan Loganathan⁷, Gianluca Sambataro⁸, Francisca Bozan⁹, Sangmee Bae¹⁰, Darosa Lim¹¹, Marta Cheli¹², Yasuhiko Yamano¹³, Francesco Bonella¹⁴, Tamera Corte¹⁵, Tracy J. Doyle¹⁶, David Fiorentino¹⁷, Miguel Gonzalez-Gay¹⁸, Marie Hudson¹⁹, Masataka Kuwana²⁰, Ingrid Lundberg²¹, Andrew Mammen²², Neil McHugh²³, Frederick Miller²⁴, Carlomaurizio Montecucco¹, Chester Oddis²⁵, Jorge Rojas-Serrano⁶, Jens Schmidt²⁶, Carlo Alberto Scirè²⁷, Albert Selva-O'Callaghan²⁸, Victoria Werth¹¹, Davide Rozza²⁹, Monica Morosini³⁰, Sara Bozzini³⁰, Lorenzo Cavagna¹, Rohit Aggarwal²⁵ and the CLASS project investigators, ¹Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ²University of Pittsburgh School of Medicine, Pittsburgh, PA, USA and University of California, San Francisco, CA, ³Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, ⁴Unidade Local de Saùde da Regiao de Aveiro and Aveiro Rheumatology Research Centre, Aveiro, Portugal; Universidade de Lisboa, Lisboa, Portugal, ⁵University of Chicago, Chicago, IL, ⁶Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Mexico City, Mexico, ⁷Royal National Hospital for Rheumatic Diseases and University of Bath, UK; Arthritis Australia, Broadway, Glebe, NSW, Australia, ⁸University of Enna "Kore", Enna, Italy, ⁹Hospital Clinico Universidad de Chile, Santiago de Chile, Chile, ¹⁰UCLA, Los Angeles, CA, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Fondazione IRCCS Istituto Neurologico C. Besta, Milano, Italy, ¹³Tosei General Hospital, Aichi, Japan, ¹⁴University of Duisburg-Essen, Essen, Germany, ¹⁵Royal Prince Alfred Hospital and University of Sydney, Sydney, Australia, ¹⁶Brigham and Women's Hospital, Boston, MA, ¹⁷Stanford University, Redwood City, CA, ¹⁸IIS-Fundación Jiménez Díaz, Madrid, Spain, ¹⁹McGill University, Montreal, QC, Canada, ²⁰Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²¹Karolinska Institutet, Stockholm, Sweden, ²²NIH, Bethesda, MD, ²³University of Bath, Bath, United Kingdom, ²⁴NIH, NIEHS, Durham, NC, ²⁵University of Pittsburgh, Pittsburgh, PA, ²⁶University Medical Center Goettingen, Goettingen, Germany, ²⁷Univeristy of Milano Bicocca, Milan, Italy and IRCCS San Gerardo dei Tintori Foundation, Monza, Italy, ²⁸Hospital Universitari Vall d'Hebron, Barcelona, Spain, ²⁹Italian Society for Rheumatology, Milano, Italy, ³⁰Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Italy
Background/Purpose: The aim of this study was to develop and validate new classification criteria for Anti-Synthetase Syndrome (ASSD) using data and consensus driven methodologies and…
Abstract Number: 0111 • ACR Convergence 2024
Comparative Performance of ELISA and CLIA Against the 2023 ACR/EULAR APS Classification Criteria
Polona Zigon¹, Nika Bostič¹, Ziga Rotar², Ales Ambrozic³, Elizabeta Blokar³, Manca ogrič¹ and Sasa Cucnik¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ³Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana
Background/Purpose: Recently published 2023 ACR/EULAR APS classification criteria emphasize delineating moderate/high anticardiolipin (aCL) and anti-β2 glycoprotein I (anti-β2GPI) antibodies. The new criteria specify the use…
Abstract Number: 2301 • ACR Convergence 2024
The Added Value of anti-Ro52 Antibody Titer in the Diagnosis of Sjögren’s Disease
Silvia Fonzetti¹, Caterina Porciani², Valentina Donati³, Davide Testa⁴, Giovanni Fulvio¹, Gaetano La Rocca¹, Inmaculada Conception Navarro García¹, Francesco Ferro⁵, Marta Mosca¹, Paola Migliorini⁶ and Chiara Baldini¹, ¹University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ²University of Pisa, Department of Clinical and Experimental Medicine - Immmunology and Allergology Unit, Pisa, Italy, ³Azienda Ospedaliero-Universitaria Pisana, Unit of Pathological Anatomy 2, Pisa, Italy, ⁴Immunology Unit, University of Pisa, Pisa, ⁵Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ⁶Immunology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Isolated anti-Ro52 antibodies (anti-Ro52) influence the ACR/EULAR 2016 classification criteria of Sjögren’s Disease (SD), meaning that patients with isolated anti-Ro52 positivity and abnormal salivary…
Abstract Number: 0116 • ACR Convergence 2024
Assessment of Triple Antiphospholipid Antibody-positive Patients Based on Clinical and Laboratory Domains of 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria
Reyhan Kose Cobanoglu¹, Joann Vega², Crystal Burgos³ and Doruk Erkan⁴, ¹Aydin Adnan Menderes University School of Medicine, Hospital for Special Surgery, NY, USA, Aydin, Turkey, ²Hospital for Special Surgery, New York, NY, New York, NY, ³Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, New York, NY
Background/Purpose: Triple aPL-positive (lupus anticoagulant test [LA], anticardiolipin antibody (aCL), and anti-β2 glycoprotein-I antibody [aβ2GPI]) patients are at higher risk to develop a severe clinical…
Abstract Number: 0117 • ACR Convergence 2024
Validation of the 2023 American College of Rheumatology/European League Against Rheumatism Antiphospholipid Syndrome Classification Criteria in the Pediatric Population
Daniel Bar¹, Stanley Niznik², Shiri Spielman³, Rotem Semo-Oz⁴, Assaf Barg³, Sarina Levy-Mendelovich³, Gili Kenet², Nancy Agmon- Levin² and Irit Tirosh⁵, ¹Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Herzliya, HaMerkaz, Israel, ²Sheba Medical Center, Tel Aviv, Israel, ³Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Tel Aviv, Israel, ⁴Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Herzliya, Israel, ⁵Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Savyon, Israel
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial, venous or microvascular thrombosis, obstetric morbidity and/or non-thrombotic manifestations. The 2023 ACR/EULAR APS…
Abstract Number: 0118 • ACR Convergence 2024
Performance of the 2023 ACR/EULAR Classification Criteria for Antiphospholipid Syndrome in a Mexican Cohort
Erik Cimé-Aké¹, Gabriela Hernández-Molina², Amaya Llorente-Chávez³ and Eduardo Martin Nares², ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Hematology Department, Mexico City, Distrito Federal, Mexico
Background/Purpose: The 2023 ACR/EULAR classification criteria (2023 AECC) for antiphospholipid syndrome (APS) were recently published. The new criteria require an entry criterion and employe a…
Abstract Number: 0125 • ACR Convergence 2024
Electronic Health Record Rule-Based Computable Phenotype of Antiphospholipid Syndrome
Emily Balczewski¹, Amala Ambati², Wenying Liang¹, Jacqueline Madison¹, Yu Zuo¹, Karandeep Singh³ and Jason Knight¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Toledo, OH, ³University of California -- San Diego, San Diego, CA
Background/Purpose: Electronic health record (EHR) data provide a widely available, inexpensive, and information-rich tool that is underutilized in the research of rare diseases like antiphospholipid…
Abstract Number: 0183 • ACR Convergence 2024
Sensitivity of 2019 EULAR/ACR SLE Criteria and Initial Organ Manifestations for Black and Hispanic Children with Juvenile Systemic Lupus Erythematosus (jSLE) at a Large Tertiary Care Center
Michelle Butts¹, Emily Beil¹, Danielle Guffey², Andrea Ramirez¹, Cagri Yildirim-Toruner³, Erin Peckham-Gregory¹ and Marietta De Guzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disorder with diverse features, posing classification challenges. In 2019, EULAR and ACR developed new classification criteria to…
Abstract Number: 0549 • ACR Convergence 2024
Global Distribution and Determinants of Diagnostic Delay Across Diverse Spondyloarthritis Entities: Data from the International ASAS-Perspa Study
Nelly Ziade¹, Sherif Gamal², Maroun Aoun³, Ihsane Hmamouchi⁴, Clementina López Medina⁵, Maxime Dougados⁶ and Bassel Elzorkany⁷, and ASAS-PerSpA, ¹Saint-Joseph University, Beirut, Lebanon, ²Cairo University, Cairo, Egypt, ³Saint Joseph University, Beirut, Lebanon, ⁴Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Rabat, Morocco, ⁵Reina Sofia University Hospital, Cordoba, Spain, ⁶Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁷Private (BZRC), Cairo, Egypt
Background/Purpose: Diagnostic delay (DD) in spondyloarthritis (SpA) is well documented, but most of the available data are reported in patients with axial SpA (axSpA). In…
Abstract Number: 0612 • ACR Convergence 2024
Performance of the Systemic Lupus Erythematosus Risk Probability Index (SLERPI): Results from the Egyptian College of Rheumatology (ECR) Study Cohort
Nevin Hammam¹, Ahmed Elsaman², Esam Abualfadl³, Soha Senara⁴, Nada M. Gamal⁵, Mona H. Abd Elsamea⁵, Abdelhfeez Moshrif⁶, Samar Tharwat⁷, Osman Hammam⁸ and Tamer A Gheita⁹, ¹Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, Boston, MA, ²Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt, ³Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt; Qena/Luxor Hospitals, Qena, Egypt, Sohag, Egypt, ⁴Rheumatology Department, Faculty of Medicine, Fayoum University,, Fayoum, Egypt, ⁵Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, Assiut, Egypt, ⁶Al-azhar university, Assiut, Egypt, ⁷Rheumatology Unit, Internal Medicine, Mansoura University, Dakahlia, ⁸Department of Rheumatology and Rehabilitation, Faculty of Medicine, New Valley University, New Valley, Assiut, Egypt, ⁹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by a great heterogeneity and unpredictable flare. In managing patients with SLE, the diagnosis…
Abstract Number: 0711 • ACR Convergence 2024
Molecular Signatures in the Skin as Predictors of Longitudinal Clinical Trajectories in Patients with Systemic Sclerosis
Natania Field¹, Monica Yang², Niket Gupta¹, Maxwell Shramuk¹, Lutfiyya Muhammad¹, Vivien Goh¹, Monica Espinoza³, Yiwei Yuan³, Rezvan Parvizi³, Kathleen Aren⁴, Mary Carns⁴, Isaac Goldberg⁵, Lorinda Chung⁶, Dinesh Khanna⁷, Zsuzsanna McMahan⁸, Michael Whitfield³ and Monique Hinchcliff⁹, ¹Northwestern Feinberg School of Medicine, Chicago, IL, ²UCSF, San Francisco, CA, ³Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Northwestern University Division of Rheumatology, Chicago, IL, ⁵Wayne State University School of Medicine, Detroit, MI, ⁶Stanford University, Woodside, CA, ⁷University of Michigan, Ann Arbor, MI, ⁸UTHealth Houston Division of Rheumatology, Houston, TX, ⁹Yale School of Medicine, Westport, CT
Background/Purpose: It has become clear that classification by phenotype is insufficient to explain the heterogeneity in clinical progression for many rheumatic diseases. Systemic sclerosis (SSc)…
Abstract Number: 0820 • ACR Convergence 2024
The Classification in Axial Spondyloarthritis Inception Cohort Study: Performance of the 2009 Assessments in Spondyloarthritis International Society Classification Criteria
Walter Maksymowych¹, Desiree van der Heijde², Liron Caplan³, Robert Landewé⁴, Lianne S Gensler⁵, Pedro M. Machado⁶, Alexandre Sepriano⁷, Floris van Gaalen⁸, Miranda van Lunteren⁹, Ben Vandermeer¹⁰, Joachim Sieper¹¹, Atul Deodhar¹² and Martin Rudwaleit¹³, and on behalf of CLASSIC Study investigators, ¹University of Alberta, Edmonton, AB, Canada, ²Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ³Rocky Mountain Regional VAMC, Aurora, CO, ⁴Amsterdam University Medical Center, Meerssen, Netherlands, ⁵Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶Department of Rheumatology, University College London Hospitals NHS Foundation Trust; and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust; and Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁷Leiden University Medical Centre, Portela Loures, Portugal, ⁸LUMC, Leiden, Zuid-Holland, Netherlands, ⁹Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ¹⁰University of Alberta, Edmonton, Canada, ¹¹Charité University Medicine Berlin, Berlin, Germany, ¹²Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ¹³University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany
Background/Purpose: The 2009 ASAS classification criteria had sensitivity of 83% and specificity of 84% for a rheumatologist diagnosis of axSpA. However, their implementation revealed varying…
Abstract Number: 1118 • ACR Convergence 2024
The Performance of Behcet’s Disease Clinical Diagnostic Criteria in a Low Prevalence Region. A Retrospective Single Center Cohort Study
Muhammad Shamim¹, Mazen Allouni², Haseeb Chaudhary³ and Omer Pamuk⁴, ¹University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ²Case Western Reserve, University Hospitals, Cleveland Medical Center, Cleveland, OH, ³Case Western Reserve University, Westlake, OH, ⁴University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: The diagnosis of Behcet’s Disease (BD) is particularly challenging in non-endemic areas because of milder disease presentations and lack of specific tests. Prior studies…
Abstract Number: 1122 • ACR Convergence 2024
Clinical Realities in Patients with Adult Onset Still’s Disease: Real-World Diagnosis and Management
Chloe Heiting¹, Karen Gambina² and Bella Mehta³, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medical College, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Adult Onset Still’s Disease (AOSD) is a rare systemic inflammatory disorder characterized by inflammatory polyarthritis, daily fever, and a transient salmon-pink maculopapular rash. Diagnosis…
Abstract Number: 1205 • ACR Convergence 2024
OARSI Initiative to Develop Classification Criteria for Early-Stage Symptomatic Knee OA (EsSKOA): What Should Be Considered in the Differential Diagnosis of EsSKOA?
Gillian Hawker¹, Lauren King¹, Jean Liew², Quike Wang³, Armaghan Mahmoudian⁴, Nuria Jansen⁵, Ian Stanaitis⁶, Jos Runhaar⁵, Tom Appleton⁷, Aleksandra Turkiewicz⁸, Martin Englund⁹, Stefan Lohmander⁹, Ida Kristin Haugen¹⁰ and Tuhina Neogi¹¹, and OARSI Early-stage Symptomatic Knee Osteoarthritis Initiative, ¹University of Toronto, Toronto, ON, Canada, ²Boston University, Boston, MA, ³Shanghai Sixth People's Hospital, Shanghai, China (People's Republic), ⁴University of West Florida, Pensacola, FL, ⁵Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, ⁶Women's College Hospital, Toronto, ON, Canada, ⁷The University of Western Ontario, London, ON, Canada, ⁸,Lund University, Lund, Sweden, ⁹Lund University, Lund, Sweden, ¹⁰Diakonhjemmet Hospital, Oslo, Norway, ¹¹Boston University Chobanian & Avedisian School of Medicine, Boston, MA
Background/Purpose: Osteoarthritis Research Society International (OARSI) has launched an initiative to develop classification criteria for early-stage symptomatic knee osteoarthritis (EsSKOA). In individuals with undiagnosed knee…

1
2
3
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.